ASCO 2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia And Malignant Pleural Mesothelioma , As Presented At The 2016 ASCO Annual Meeting /PRNewswire/ — SELLAS Life Sciences Group , a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancer, today announced that promising results from a Phase 2 trial of galinpepimut-S, the Company's WT1 cancer vaccine, in patients with acute myeloid leukemia were presented in an oral presentation at the Annual Meeting of the American Society of Clinical Oncology , being held in .
